Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities
File(s)Fotopoulou et al Arch Gyn Obs - FINAL.docx (63.62 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
OBJECTIVE: To assess surgical morbidity and mortality of maximal effort cytoreductive surgery for disseminated epithelial ovarian cancer (EOC) in a UK tertiary center. METHODS/MATERIALS: A monocentric prospective analysis of surgical morbidity and mortality was performed for all consecutive EOC patients who underwent extensive cytoreductive surgery between 01/2013 and 12/2014. Surgical complexity was assessed by the Mayo clinic surgical complexity score (SCS). Only patients with high SCS ≥5 were included in the analysis. RESULTS: We evaluated 118 stage IIIC/IV patients, with a median age of 63 years (range 19-91); 47.5 % had ascites and 29 % a pleural effusion. Median duration of surgery was 247 min (range 100-540 min). Median surgical complexity score was 10 (range 5-15) consisting of bowel resection (71 %), stoma formation (13.6 %), diaphragmatic stripping/resection (67 %), liver/liver capsule resection (39 %), splenectomy (20 %), resection stomach/lesser sac (26.3 %), pleurectomy (17 %), coeliac trunk/subdiaphragmatic lymphadenectomy (8 %). Total macroscopic tumor clearance rate was 89 %. Major surgical complication rate was 18.6 % (n = 22), with a 28-day and 3-month mortality of 1.7 and 3.4 %, respectively. The anastomotic leak rate was 0.8 %; fistula/bowel perforation 3.4 %; thromboembolism 3.4 % and reoperation 4.2 %. Median intensive care unit and hospital stay were 1.7 (range 0-104) and 8 days (range 4-118), respectively. Four patients (3.3 %) failed to receive chemotherapy within the first 8 postoperative weeks. CONCLUSIONS: Maximal effort cytoreductive surgery for EOC is feasible within a UK setting with acceptable morbidity, low intestinal stoma rates and without clinically relevant delays to postoperative chemotherapy. Careful patient selection, and coordinated multidisciplinary effort appear to be the key for good outcome. Future evaluations should include quality of life analyses.
Date Issued
2016-04-04
Date Acceptance
2016-03-17
Citation
Gynecologic Oncology, 2016
ISSN
1095-6859
Publisher
Springer
Journal / Book Title
Gynecologic Oncology
Volume
2016
Copyright Statement
© Springer-Verlag Berlin Heidelberg 2016. The final publication is available at Springer via htpp://dx.doi.org/10.1007/s00404-016-4080-3
Identifier
PII: 10.1007/s00404-016-4080-3
Subjects
Albumin
Cytoreduction
Morbidity
Mortality
Multivisceral
Ovarian cancer
Obstetrics & Reproductive Medicine
Oncology & Carcinogenesis
1114 Paediatrics And Reproductive Medicine
1112 Oncology And Carcinogenesis
Publication Status
Published